PARIS (dpa-AFX) - Sanofi (SNY, SNYNF.PK) announced, at the 71st Scientific American Diabetes Association Sessions 2011, the results of three studies showing that people with diabetes using Sanofi insulins Lantus and/or Apidra with the insulin delivery device SoloSTAR experienced greater treatment satisfaction, better quality of life and lower fear of hypoglycemia vs those using a premixed insulin product.
The company noted that the goal of the first study, involving 586 patients with uncontrolled type 2 diabetes on oral agents, was to evaluate any changes in physical and psychological well-being, diabetes-related symptoms, and patient satisfaction with diabetes-related care and treatment over the study period and from baseline to endpoint.
The company stated that the study demonstrated that, compared with those on twice-daily premixed 70/30 insulin aspart, patients on the combination of Lantus- and Apidra-based regimens experienced better quality of life as measured by the Diabetes Quality of Life questionnaire, which evaluates personal perception of improvements as a result of treatment.
The goal of the second study was to evaluate the change in diabetes treatment satisfaction in people treated with insulin glargine. It showed that 96% of patients experienced significant treatment satisfaction upon switching to Lantus SoloSTAR from their previous treatment: Diabetes Treatment Satisfaction Questionnaire at 6 months = 12.0, compared to overall satisfaction at baseline.
Copyright RTT News/dpa-AFX
© 2011 AFX News
